Simris Group

0.07 SEK

+10.40 %

Less than 1K followers

SIMRIS B

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

+10.40 %

+68.69 %

+59.03 %

-36.39 %

-56.64 %

-16.44 %

-82.41 %

-88.55 %

-98.70 %

Simris Group is a biotechnology company. The company is focused on research and development of bioactive substances from cultured microalgae, for applications in nutrition, cosmeceuticals and pharmaceuticals. The company's technology also replaces unsustainable raw materials from endangered species and sensitive marine ecosystems. Simris Group was founded in 2011 and is headquartered in Hammenhög.

Market cap

60.8M SEK

Turnover

32.43K SEK

Revenue

2.89M

EBIT %

-1,201.04 %

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

25.2

2026

Annual report '25

13.5

2026

Interim report Q1'26

27.5

2026

General meeting '26

All

Press releases

3rd party

ShowingAll content types

Regulatory press release1/19/2026, 3:30 PM

Bulletin from Simris Group AB’s extraordinary general meeting

Press release1/19/2026, 1:00 PM

Simris Group enters into Memorandum of Understanding regarding divestment of assets in Hammenhög

Regulatory press release12/16/2025, 8:32 PM

Simris Group AB (publ) receives notice of conversion of convertible bonds

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release12/16/2025, 7:45 PM

Notice of extraordinary general meeting in Simris Group AB (publ)

Regulatory press release12/16/2025, 7:43 PM

Simris Group AB resolves on directed issue of units, proposes that an extraordinary general meeting resolves on additional share issues and announces acceptance of premature conversion of convertible debentures

Regulatory press release11/28/2025, 3:51 PM

Simris Group enters into bridge loan agreement

Regulatory press release11/12/2025, 7:00 AM

SIMRIS GROUP INTERIM REPORT JANUARY-SEPTEMBER 2025

Regulatory press release11/10/2025, 7:30 AM

Simris Group announces leadership transition - Daniel Kubitza appointed interim CEO

Regulatory press release11/5/2025, 12:00 PM

Simris Group AB Announces Positive Results from Ongoing Antibody-Drug Conjugate (ADC) Study with Nuvisan

Regulatory press release10/6/2025, 7:30 AM

Update Regarding In-Vitro Evaluation of Novel Advance Microcystin Payloads

Press release9/12/2025, 8:00 AM

Simris Biologics awarded €200K in non-dilutive funding for R&D programme to further develop microcystin payloads for Antibody Drug Conjugates (ADCs)

Regulatory press release8/13/2025, 6:00 AM

SIMRIS GROUP INTERIM REPORT JANUARY-JUNE 2025

Regulatory press release7/27/2025, 7:57 PM

Simris Group AB (publ) resolves on a directed issue of convertible debentures of EUR 678,000 and amends existing loan facilities

Regulatory press release7/12/2025, 4:38 AM

Partner Company Decides Not to Proceed with Simris Group ADC Proposed Collaboration Following Strategic Review

Press release6/5/2025, 7:15 AM

Simris Biologics Signs Agreement with Nuvisan for In-Vivo Evaluation of Novel Microcystin Payloads

Regulatory press release6/2/2025, 6:55 AM

Simris Group AB Signs Non-Binding Concept Sheet for Potential Antibody-Drug Conjugate Collaboration

Regulatory press release5/28/2025, 3:10 PM

Bulletin from Simris Group AB’s annual general meeting

Regulatory press release5/14/2025, 6:00 AM

SIMRIS GROUP INTERIM REPORT JANUARY-MARCH 2025

Regulatory press release4/25/2025, 1:00 PM

Notice of the Annual General Meeting of Simris Group AB (publ)

Regulatory press release4/16/2025, 4:05 PM

Simris Group enters into bridge loan agreement, extends loan agreements with investors and intends to propose that the annual general meeting resolves to extend loan agreements with management

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.